Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080402 | 0.88 | NTRK1 (0.36) | NTRK1MEN1KMT2A | |
| SCHEMBL16631917 | 0.82 | DPP4 (0.35) | EP300 | |
| SCHEMBL18081748 | 0.80 | EP300 (0.40) | EP300 | |
| SCHEMBL16631731 | 0.77 | KCNMA1 (0.54) | EP300 | |
| SCHEMBL16631733 | 0.76 | CYP19A1 (0.51) | MEN1KMT2A | |
| SCHEMBL16631908 | 0.75 | PTGDR2 (0.38) | — | |
| SCHEMBL16631910 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16631326 | 0.74 | EGLN2 (0.36) | — | |
| SCHEMBL18080398 | 0.74 | DPP4 (0.33) | NTRK1EP300 | |
| SCHEMBL18080403 | 0.72 | EP300 (0.36) | EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | NTRK1 1530/4885EP300 4033/4885MEN1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.